Clinical Trials
NX-5948 in patients w/relapsed/refractory CLL or SLL previously treated w/a BTKi and a BCL-2i
Disease Type: Leukemia , Disease Type: Lymphoma
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville